AxoGen surges after upbeat annual revenue outlook

By Reuters News15:39 (UTC), 28 October 2026 Updated

** Shares of surgical device maker AxoGen AXGN.O gain 30.3% to $48.79

** Stock set for biggest one-day percentage gain in over two years if gains hold

** Co forecasts FY revenue of $290 mln, above analysts' estimates of $283.2 mln

** AXGN also posts Q3 revenue of $75.80 mln, beating analysts' estimates of $73.20 mln, shows LSEG-compiled data

** Eleven brokerages covering the stock rate it "buy" or higher; their median PT is $53- LSEG-compiled data

** Including session's moves, shares up 42.5% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.